[
  {
    "ts": "2025-09-18T12:30:00+00:00",
    "headline": "Vertex Announces CASGEVY速 Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy",
    "summary": "LONDON, September 18, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY速 (exagamglogene autotemcel).",
    "url": "https://finance.yahoo.com/news/vertex-announces-casgevy-reimbursement-agreement-123000759.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "ab0b1044-9a8e-3c8f-bd4f-2113cc34dee7",
      "content": {
        "id": "ab0b1044-9a8e-3c8f-bd4f-2113cc34dee7",
        "contentType": "STORY",
        "title": "Vertex Announces CASGEVY速 Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy",
        "description": "",
        "summary": "LONDON, September 18, 2025--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY速 (exagamglogene autotemcel).",
        "pubDate": "2025-09-18T12:30:00Z",
        "displayTime": "2025-09-18T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/0dc8960fd7f3eac0b6c8573c2c713f5a",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hFYxtKwXMVtiKamo_B1_0w--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0dc8960fd7f3eac0b6c8573c2c713f5a.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/XSytvej49Ki9GtbZguiCuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0dc8960fd7f3eac0b6c8573c2c713f5a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-casgevy-reimbursement-agreement-123000759.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-casgevy-reimbursement-agreement-123000759.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]